US2014294776A1PendingUtilityA1

Isolated populations of female germline stem cells and cell preparations and compositions thereof

57
Assignee: GEN HOSPITAL CORPPriority: May 17, 2004Filed: Jan 21, 2014Published: Oct 2, 2014
Est. expiryMay 17, 2024(expired)· nominal 20-yr term from priority
Inventors:Jonathan L. TillyJoshua Johnson
A01K 2267/0393A01K 2227/105A01K 67/0275C12N 5/0611A01K 2217/05A61K 35/54A61P 15/18A01K 67/0271C12N 5/0607C12N 15/8775A61P 15/08
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to female germline stem cells and their progenitors, methods of isolation thereof, and methods of use thereof.

Claims

exact text as granted — not AI-modified
We claim: 
     
         1 . An isolated population of mitotically active non-embryonic stem cells expressing Vasa, Oct-4, Dazl, Stella and optionally a stage-specific embryonic antigen prepared by a process comprising selecting cells in a sample of mammalian ovarian tissue based on expression of a first genetic marker selected from a stage-specific embryonic antigen, Vasa, Oct-4, Dazl or Stella. 
     
     
         2 . The isolated population of  claim 1 , wherein the mammalian ovarian tissue is human ovarian tissue. 
     
     
         3 . The isolated population of  claim 1 , wherein the first genetic marker is a stage-specific embryonic antigen. 
     
     
         4 . The isolated population of  claim 1 , wherein the first genetic marker is Vasa. 
     
     
         5 . The isolated population of  claim 1 , wherein the first genetic marker is Oct-4. 
     
     
         6 . The isolated population of  claim 1 , wherein the first genetic marker is Dazl. 
     
     
         7 . The isolated population of  claim 1 , wherein the first genetic marker is Stella. 
     
     
         8 . The isolated population of  claim 1 , wherein selecting cells based on the first genetic marker comprises selecting mRNA or protein corresponding to the first genetic marker. 
     
     
         9 . The isolated population of  claim 1 , wherein selecting cells based on the first genetic marker comprises fluorescence activated cell sorting (FACS). 
     
     
         10 . The isolated population of  claim 1 , wherein the process further comprises culturing the selected cells. 
     
     
         11 . A cell preparation comprising the isolated population of  claim 1  and a pharmaceutically acceptable carrier. 
     
     
         12 . The isolated population of  claim 1 , wherein the cells are further selected based on expression of a second genetic marker selected from a stage-specific embryonic antigen, Vasa, Oct-4, Dazl or Stella, wherein the second genetic marker is different from the first genetic marker. 
     
     
         13 . The isolated population of  claim 12 , wherein the second genetic marker is a stage-specific embryonic antigen. 
     
     
         14 . The isolated population of  claim 12 , wherein the second genetic marker is Vasa. 
     
     
         15 . The isolated population of  claim 12 , wherein the second genetic marker is Oct-4. 
     
     
         16 . The isolated population of  claim 12 , wherein the second genetic marker is Dazl. 
     
     
         17 . The isolated population of  claim 12 , wherein the second genetic marker is Stella. 
     
     
         18 . The isolated population of  claim 12 , wherein selecting cells based on the second genetic marker comprises selecting mRNA or protein corresponding to the second genetic marker. 
     
     
         19 . The isolated population of  claim 12 , wherein selecting cells based on the second genetic marker comprises fluorescence activated cell sorting (FACS). 
     
     
         20 . The isolated population of  claim 12 , wherein the process further comprises culturing the selected cells. 
     
     
         21 . A composition comprising a cell preparation of isolated non-embryonic stem cells that are mitotically competent and express Vasa, Oct-4, Dazl, Stella and optionally a stage-specific embryonic antigen, wherein the non-embryonic stem cells are isolated from mammalian ovarian tissue. 
     
     
         22 . The composition of  claim 21 , wherein the non-embryonic stem cells are female germline cells. 
     
     
         23 . The composition of  claim 21 , wherein the non-embryonic stem cells are isolated from human ovarian tissue. 
     
     
         24 . The composition of  claim 21 , wherein the expression of one or more of Vasa, Oct-4, Dazl, Stella or a stage specific antigen is determined by detecting mRNA, protein, or a combination thereof. 
     
     
         25 . The composition of  claim 21 , wherein the cells are isolated by a process comprising fluorescence activated cell sorting. 
     
     
         26 . The composition of  claim 21 , further comprising cell culture medium. 
     
     
         27 . The composition of  claim 21 , further comprising a pharmaceutically acceptable carrier. 
     
     
         28 . The composition of  claim 21 , wherein the non-embryonic stem cells are cultured. 
     
     
         29 . The composition of  claim 28 , further comprising cell culture medium. 
     
     
         30 . The composition of  claim 28 , further comprising a pharmaceutically acceptable carrier.

Join the waitlist — get patent alerts

Track US2014294776A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.